Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population (APOGEE)
Primary Purpose
Fovea Plana, Albinism
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Genetic analysis
Ophthalmologic exam
Sponsored by
About this trial
This is an interventional screening trial for Fovea Plana focused on measuring Carriers, General population
Eligibility Criteria
Inclusion Criteria:
- Patient over 18 years old;
- Diagnosis of fovea plana in one or both eyes, confirmed by two ophthalmologists blinded to each other from OCT-B imaging;
Exclusion Criteria:
- Known Albinism
- Known family history of albinism
- History of eye surgery other than cataract
- Alteration of macular visual function (loss of visual acuity independent of a disorder of the environments, central scotoma, metamorphopsies, etc.)
- Presence of another anomaly in OCT in addition to the fovea plana (epiretinal membrane, damage to the external retina, etc.)
- Syndromic fovea plana
- Pregnant or breastfeeding woman
Sites / Locations
- Hôpital Fondation A. de RothschuldRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Genetic analysis
Arm Description
Outcomes
Primary Outcome Measures
Describe the results of genetic analysis for the various variants of known genes involved in albinism and in genetic pathologies associated with fovea plana
Genetic sampling carried out for the study. Patient exome sequencing. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana
Secondary Outcome Measures
Full Information
NCT ID
NCT04658381
First Posted
December 1, 2020
Last Updated
August 2, 2023
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
1. Study Identification
Unique Protocol Identification Number
NCT04658381
Brief Title
Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population
Acronym
APOGEE
Official Title
Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 17, 2020 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Albinism is a genetic condition, resulting from mutations in at least 19 known genes responsible for the production of melanin in the skin, hair and eyes.
Ophthalmological manifestations are a constant feature of this disease. Albinism is believed to be responsible for 5% of visual impairments worldwide and all albino patients have some degree of fovea plana. In the milder forms, it is a slightly less marked foveolar depression with conservation of the normal diameter of the cones and, therefore, good visual function.
In addition to its known association with various ocular pathologies such as albinism, aniridia, nanophthalmia and retinopathy of prematurity, fovea plana was found in 3% of a population of normal children (without known ocular or systemic pathology) in a study conducted in 2014 to determine a pediatric normative basis for macular volume measured by optical coherence imaging (Stratus OCT).
More recently, a study carried out at the Hospital Foundation Adolphe de Rothschild showed that at least 35% of parents of albino children, who are totally asymptomatic, present with fovea plana in OCT. This frequency is higher than the 3% prevalence of fovea plana in asymptomatic subjects without a family history of albinism, suggesting a modulation of heterozygosity for a known gene for albinism.
The aim of this study is to verify, in patients with fortuitously discovered fovea plana (preoperative OCT for cataract surgery), with conservation of visual function and without known or manifest albinism, whether they are carriers of mutation in one of the genes referenced for albinism. This will also allow us to characterize these foveolar profiles in OCT according to the classification of Thomas et al., as well as in terms of retinal capillary density in OCT-Angiography, in order to know whether it is the same type of fovea plana or if the phenotype differs depending on the genetic damage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fovea Plana, Albinism
Keywords
Carriers, General population
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Genetic analysis
Arm Type
Experimental
Intervention Type
Genetic
Intervention Name(s)
Genetic analysis
Intervention Description
Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
Intervention Type
Procedure
Intervention Name(s)
Ophthalmologic exam
Intervention Description
Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
Primary Outcome Measure Information:
Title
Describe the results of genetic analysis for the various variants of known genes involved in albinism and in genetic pathologies associated with fovea plana
Description
Genetic sampling carried out for the study. Patient exome sequencing. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient over 18 years old;
Diagnosis of fovea plana in one or both eyes, confirmed by two ophthalmologists blinded to each other from OCT-B imaging;
Exclusion Criteria:
Known Albinism
Known family history of albinism
History of eye surgery other than cataract
Alteration of macular visual function (loss of visual acuity independent of a disorder of the environments, central scotoma, metamorphopsies, etc.)
Presence of another anomaly in OCT in addition to the fovea plana (epiretinal membrane, damage to the external retina, etc.)
Syndromic fovea plana
Pregnant or breastfeeding woman
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amélie YAVCHITZ, MD
Phone
(0)1 48 03 64 33
Ext
+33
Email
ayavchitz@for.paris
First Name & Middle Initial & Last Name or Official Title & Degree
Raphaël LEJOYEUX, MD
Email
rlejoyeux@for.paris
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raphaël LEJOYEUX, MD
Organizational Affiliation
Hôpital Fondation A. de Rothschild
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Fondation A. de Rothschuld
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raphaël LEJOYEUX
12. IPD Sharing Statement
Learn more about this trial
Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population
We'll reach out to this number within 24 hrs